China Securities Co.,Ltd. is bullish on pharmaceutical companies participating in industry consolidation domestically and actively exploring overseas markets.

Looking ahead to future investment opportunities in the Industry, the bank is Bullish on pharmaceutical companies stabilizing their domestic foundations, actively participating in industry consolidation, managing the rhythm and path externally, and proactively exploring overseas markets.

Zhitong FinanceMay 13 10:09

[Brokerage Focus] China Securities Co.,Ltd.: Bullish on pharmaceutical companies to stabilize domestic foundations while actively exploring overseas markets.

Jinwu Financial News | China Securities Co.,Ltd. released a Research Report, stating that against the backdrop of a reshaped Global landscape, the China pharmaceutical Industry needs to "base itself internally and explore externally," promote technological autonomy, accelerate international layout, respond to tariff policies and geopolitical challenges, and seize opportunities for transformation in the global pharmaceutical Industry Chain. In the recent tariff increases by the USA on China, the phased exemption for Pharmaceuticals and the export of Innovative Drugs mainly through IP transfer have limited impact. The firm remains Bullish on the Medical Device Industry's trend towards autonomy and export. Looking ahead at future investment opportunities in the Industry, the firm is optimistic about pharmaceutical companies stabilizing their domestic foundations while actively participating in industry consolidation and capturing external opportunities.

King Wu Financial News.May 13 08:51

E Fond Fund increased its shareholding in TIGERMED (03347) by 0.1635 million shares at an approximate price of 27.29 Hong Kong dollars per share.

On May 8, E Fund increased its shareholding in TIGERMED (03347) by 0.1635 million shares, at a price of 27.2934 HKD per share, totaling approximately 4.4625 million HKD.

Zhitong FinanceMay 12 17:46

TIGERMED (03347.HK) was increased by E Fund Management Co., Ltd. by 0.1635 million shares of H shares, valued at approximately 4.4625 million Hong Kong dollars.

On May 12, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 12, E Fund Management Co., Ltd. increased its shareholding of $TIGERMED (03347.HK) by 0.1635 million shares of Listed in Hong Kong at an average price of 27.2934 HKD per share on May 8, with a value of approximately 4.4625 million HKD. After the increase, E Fund Management Co., Ltd.'s latest shareholding stands at 9.9269 million shares, raising the shareholding ratio from 7.93% to 8.06%. Image source: Stock disclosure from the Exchange. What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more) are required...

Futu NewsMay 12 17:06

Did Trump’s "order" cause a collapse in global drug prices? Hong Kong A shares in the pharmaceutical sector reacted quickly!

Trump wants to lower drug prices?

Gelonghui FinanceMay 12 14:01

The Concept of Innovative Drugs has been severely attacked! Trump suddenly posts: We need to reduce drug prices in the USA by up to 80% immediately!

① The President of the USA, Trump, will sign an executive order on Monday aimed at reducing the prices of USA prescription pharmaceuticals and medications by 30% to 80% immediately; ② The executive order will implement a "most-favored-nation policy," aligning the prices paid in the USA with those of the country with the lowest drug prices in the world; ③ Trump referred to this executive order as "one of the most important executive orders in USA history," expecting it to save trillions of dollars.

cls.cnMay 12 11:24